Say Hello!
Don’t be shy.

   

Investment Tag

MediCity, Nottingham based Locate Bio, which is developing new treatments for patients with serious spinal conditions has completed a £2.25m funding round led by Mercia Asset Management to help to continue its research and bring its first products to market. Locate Bio has secured the investment...

Excellerate Bioscience is delighted that a close relationship with Omass Therapeutics, built over 18 months, has helped contribute to their success in securing extended series A funding. During this period, Excellerate assembled a dedicated team of expert pharmacologists focussed exclusively on driving forward the Omass...

Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based BioMotiv   Glasgow, Scotland, 7 April 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes...

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) has significantly increased its tablet manufacturing capabilities following a strategic investment in a new state-of the-art tablet press. This investment will enhance the company’s development and manufacturing capabilities whilst strengthening their ability to support...

Cheshire UK, 29 August 2019 BioCity, the pioneering life science incubator and business collective, has today announced investment in precision medicine biotech, Kinomica Ltd., via the Innovate UK Precision Medicine Investment Accelerator. Spun out from Barts Cancer Institute, Queen Mary University of London, Kinomica Ltd is an...

BioCity, the pioneering life science and business collective has announced co-investment into Rinri Therapeutics. A biotechnology company developing a novel cell-based therapy to restore hearing, Rinri Therapeutics have successfully secured £1.4 million in seed funding. BioCity’s recent investment in the biotech company, marks the 28th investment...

X
X
X
X